• Type of Event: The document is a transcript of Sun Pharmaceutical Industries Limited's Q1 FY27 Financial Results Conference Call, which included an earnings presentation and a question-and-answer session with analysts.
  • Date and Time: The conference call was held on July 31, 2026, at 06:30 pm. The transcript was filed with the exchanges on August 06, 2026.
  • Stated Purpose: The purpose of the call was to "provide an update on financial performance and business highlights for the quarter, pipeline updates and respond to any queries."
  • Earnings Announcement Timing: The call was held after the earnings announcement, as the financials, press release, and earnings presentation had been sent out earlier on the day of the call.
  • Management Participants: The following management participants were present on the call:
  • Mr. Dilip Shanghvi, Chairman
  • Mr. Kirti Ganorkar, Managing Director
  • Mr. Aalok Shanghvi, Chief Operating Officer
  • Ms. Jayashree Satagopan, Chief Financial Officer
  • Mr. Richard Ascroft, CEO (North America)
  • Dr. Abhishek Sharma, Vice President and Head of Investor Relations and Strategic Projects (Moderator)
  • Availability of Materials: The company confirmed that the Q1 financials, press release, and earnings presentation were sent out earlier and are available on the company's website. The call recording and transcript were also stated to be put up on the website shortly.
  • UPSI Statement: The company explicitly stated that no questions would be taken regarding Organon's business performance as it remains a publicly listed company, implying adherence to compliance regarding unpublished information. The discussion included forward-looking statements with a standard risk disclaimer.

Financial Period Discussed: The call exclusively discussed the financial and operational performance for Q1 FY27 (the quarter ending June 2026).

Key Financial Highlights from the Call:

  • Sales: Consolidated sales were INR 1,51,836 million, registering a growth of 10.1% versus Q1 FY26.
  • Gross Margin: Was 80.5% for the quarter, higher than the same period last year, attributed to a better product mix.
  • EBITDA: Was INR 44,177 million, an increase of 2.7% over Q1 last year. EBITDA margins were 28.9%.
  • Net Profit: Reported net profit after tax was INR 28,948 million. Adjusted net profit for the quarter was INR 30,894 million.
  • EPS: Was INR 12.10 per share.
  • Exceptional Items: Included a charge of INR 1,617 million towards Organon's acquisition-related costs. Additional charges are expected in subsequent quarters, accruing substantially at closing.
  • Tax Rate: The effective tax rate (ETR) for the quarter was 27.8%, up from 24.3% in Q1 FY26, due to the exhaustion of lower tax rates in India. The ETR is expected to remain in a similar range until the Organon acquisition closes.
  • Balance Sheet: The company reported a strong balance sheet with a net cash position of $3.4 billion at the consolidated level.

Business Performance Highlights:

  • Global Innovative Medicines: Sales were USD 351 million, up 12.8% YoY, accounting for 21.9% of total sales. Growth was driven by ILUMYA, ODOMZO, and CEQUA across U.S. and ex-U.S. markets. Updated data for Unloxcyt was presented at the 2026 ASCO Annual Meeting.
  • India Formulations: Sales were INR 54,749 million, recording a growth of 16% YoY and accounting for 36.1% of total sales. The company is ranked #1 in the Indian pharmaceutical market with an 8.5% share (Pharmarack MAT June 2026). Growth was driven by a 5.4% volume expansion (vs. IPM growth of 2%) and new product launches, including becoming the #2 generic semaglutide injectable player.
  • U.S. Business: Sales were USD 427 million, declining by 9.7% YoY. The decline was attributed to Lenalidomide erosion and additional competition in the generics portfolio, partially offset by growth in Innovative Medicines. Five generic products were launched in the U.S. during the quarter. Updates were provided on the ongoing launches of Leqselvi (surpassed 1,000 prescribers in June) and Unloxcyt (positive early feedback).
  • Emerging Markets: Formulations revenues were USD 311 million, up 4.2% YoY, accounting for 19.4% of total sales. Growth was driven by branded generics and Innovative Medicines like ILUMYA.
  • Rest of the World (ROW): Formulations revenues were USD 218 million, marginally lower YoY, accounting for 13.6% of total sales. The company received approvals for generic semaglutide in Brazil and South Africa, with a launch already completed in South Africa.
  • R&D: Consolidated R&D investment was INR 8,264 million, or 5.4% of sales. Innovative R&D accounted for 30% of the total R&D spend. Partner Philogen resubmitted Nidlegy for marketing authorization in Europe.
  • Organon Acquisition: The process of filing for regulatory approvals in various markets is complete, with approvals received in certain countries. Organon shareholders have approved the transaction. The acquisition is on track to close by early 2027 (Q4 FY27). An integration management office is working on day-one preparedness.

Forward-Looking Statements & Guidance:

Management reiterated its full-year guidance for "high single-digit growth" in revenue. They indicated that the effective tax rate is expected to remain around the Q1 level (~28%) until the Organon deal closes.

Additional Notes Section

  • The document is a verbatim transcript of the earnings conference call, which was attached to a regulatory filing submitted to the stock exchanges.
  • No standalone financial data or presentation decks were included within this specific transcript document; they were referenced as being available separately on the company's website.
  • The transcript contains extensive logistical details of the Q&A session, including the names of analysts and their firms, which is typical for such earnings call transcripts.